NRF-2 polyclonal Antibody | GCP86

NRF-2 polyclonal Antibody | GCP86 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Pig

Application: WB IHC

Application Range: WB: 1:1000~1:2000 IHC: 1:50~1:200

Background: The nuclear factor-like 2 (NRF2) transcriptional activator binds antioxidant response elements (ARE) of target gene promoter regions to regulate expression of oxidative stress response genes. Under basal conditions, the NRF2 inhibitor INrf2 (also called KEAP1) binds and retains NRF2 in the cytoplasm where it can be targeted for ubiquitin-mediated degradation. Small amounts of constitutive nuclear NRF2 maintain cellular homeostasis through regulation of basal expression of antioxidant response genes. Following oxidative or electrophilic stress, KEAP1 releases NRF2, thereby allowing the activator to translocate to the nucleus and bind to ARE-containing genes. The coordinated action of NRF2 and other transcription factors mediates the response to oxidative stress. Altered expression of NRF2 is associated with chronic obstructive pulmonary disease (COPD) . NRF2 activity in lung cancer cell lines directly correlates with cell proliferation rates, and inhibition of NRF2 expression by siRNA enhances anti-cancer drug-induced apoptosis.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: NRF-2 polyclonal Antibody detects endogenous levels of NRF-2 protein.

Molecular Weight: ~ 90 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Nuclear factor erythroid 2-related factor 2; NF-E2-related factor 2; NFE2-related factor 2; Nrf-2; HEBP1; Nuclear factor, erythroid derived 2, like 2; NFE2L2; NRF2

Immunogen: Synthetic peptide, corresponding to Human NRF-2.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: N/A